Abstract
Maintenance treatments show clinically meaningful survival benefits in good performance status patients with advanced NSCLC not progressing after first-line chemotherapy. Benefits are optimised by targeting specific maintenance to individual patients guided by PS, EGFR mutation status, histology and response to induction.
Keywords
PemetrexedMedicineOncologyInternal medicineMaintenance therapyLung cancerGemcitabineDocetaxelHazard ratioRegimenPerformance statusEpidermal growth factor receptorCancerChemotherapyConfidence interval
Affiliated Institutions
Related Publications
A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer
Our aim was to evaluate the clinical effectiveness of chemotherapy treatments currently licensed in Europe and recommended by the National Institute for Health and Care Excellen...
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...
Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro).
9026 Background: The anti–PD-1 antibody pembro (MK-3475) is approved in the US for treating PD-L1–positive NSCLC that progressed after platinum-containing chemotherapy. This app...
Publication Info
- Year
- 2015
- Type
- review
- Volume
- 51
- Issue
- 16
- Pages
- 2330-2344
- Citations
- 17
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
17
OpenAlex
Cite This
Pui San Tan,
Gilberto Lopes,
Sanchalika Acharyya
et al.
(2015).
Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction.
European Journal of Cancer
, 51
(16)
, 2330-2344.
https://doi.org/10.1016/j.ejca.2015.07.007
Identifiers
- DOI
- 10.1016/j.ejca.2015.07.007